Identification of a Five-Gene Signature and Establishment of a Prognostic Nomogram to Predict Progression-Free Interval of Papillary Thyroid Carcinoma

被引:28
|
作者
Wu, Mengwei [1 ]
Yuan, Hongwei [1 ]
Li, Xiaobin [1 ]
Liao, Quan [1 ]
Liu, Ziwen [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China
来源
关键词
TCGA; GEO; papillary thyroid carcinoma; progression-free interval; nomogram; BETA RECEPTOR; CELL-PROLIFERATION; CANCER; GENE; EXPRESSION; NODULES; GROWTH; FXYD6; LIVER; OSTEOSARCOMA;
D O I
10.3389/fendo.2019.00790
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The incidence of papillary thyroid carcinoma (PTC) is high and increasing worldwide. Although prognosis is relatively good, it is important to select the minority of patients with poorer prognosis to avoid side effects associated with unnecessary over-treatment in low-risk patients; this requires accurate prognostic predictions. Materials and Methods: Six PTC expression datasets were obtained from the gene expression omnibus (GEO) database. Level 3 mRNA expression and clinicopathological data were obtained from The Cancer Genome Atlas Thyroid Cancer (TCGA-THCA) database. Through integrated analysis of these datasets, highly reliable differentially-expressed genes (DEGs) between tumor and normal tissue were identified and lasso Cox regression was applied to identify DEGs related to the progression-free interval (PFI) and to establish a prognostic gene signature. The performance of a five-gene signature was evaluated based on a Kaplan-Meier curve, receiver operating characteristic (ROC), and Harrell's concordance index (C-index). Multivariate Cox regression analysis was used to identify factors associated with PTC prognosis. Finally, a prognostic nomogram was established based on the TCGA-THCA dataset. Results: A novel five-gene signature was established to predict the PTC PFI, which included PLP2, LYVE1 , FABP4, TGFBR3, and FXYD6, and the ROC curve and C-index showed good performance in both training and validation datasets. This could classify patients into high- and low-risk groups with distinct PFIs and differentiate PTC tumors from normal tissue. Univariate Cox regression revealed that this signature was an independent prognostic factor for PTC. The established nomogram, incorporating the prognostic gene signature and clinical parameters, was able to predict the PFI with high efficiency. The gene signature-based nomogram was superior to the American Thyroid Association (ATA) risk stratification to predict PTC PFI. Conclusions: Our study identified a five-gene signature and established a prognostic nomogram, which were reliable in predicting the PFI of PTC; this could be beneficial for individualized treatment and medical decision making.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] A Five-Gene Signature Associated With DNA Damage Repair Molecular Subtype Predict Overall Survival for Hepatocellular Carcinoma
    Huo, Junyu
    Fan, Xinyi
    Qi, Bingxin
    Sun, Peng
    FRONTIERS IN GENETICS, 2022, 13
  • [42] Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
    Li, Jiayi
    Cao, Dongyan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [43] Development and validation of a ferroptosis-related prognostic model for the prediction of progression-free survival and immune microenvironment in patients with papillary thyroid carcinoma
    Huang, Yinde
    Xie, Zhenyu
    Li, Xin
    Chen, Wenbin
    He, Yuzhen
    Wu, Song
    Li, Xinyang
    Hou, Bingchen
    Sun, Jianjian
    Wang, Shiyue
    He, Yuchen
    Jiang, Han
    Lun, Yu
    Zhang, Jian
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 101
  • [44] Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer
    Wu, Mengwei
    Li, Xiaobin
    Zhang, Taiping
    Liu, Ziwen
    Zhao, Yupei
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [45] A Radiomics Signature-Based Nomogram to Predict the Progression-Free Survival of Patients With Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation
    Fang, Shiji
    Lai, Linqiang
    Zhu, Jinyu
    Zheng, Liyun
    Xu, Yuanyuan
    Chen, Weiqian
    Wu, Fazong
    Wu, Xulu
    Chen, Minjiang
    Weng, Qiaoyou
    Ji, Jiansong
    Zhao, Zhongwei
    Tu, Jianfei
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [46] Reply to letter commenting on: A five-gene expression signature to predict progression in T1G3 bladder cancer
    van der Heijden, Antoine G.
    Mengual, Lourdes
    EUROPEAN JOURNAL OF CANCER, 2016, 68 : 198 - 198
  • [47] Development and validation of a prognostic nomogram for progression-free survival in patients with advanced renal cell carcinoma treated with pazopanib
    Kattan, Michael W.
    Sternberg, Cora N.
    Mehmud, Faisal
    Bhatt, Kamal
    McCann, Lauren
    Motzer, Robert J.
    ONKOUROLOGIYA, 2015, 11 (04): : 16 - 23
  • [48] Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
    Kattan, Michael W.
    Sternberg, Cora N.
    Mehmud, Faisal
    Bhatt, Kamal
    McCann, Lauren
    Motzer, Robert J.
    ONCOLOGY, 2015, 89 (04) : 235 - 241
  • [49] Identification of a Signature Comprising 5 Soluble Carrier Family Genes to Predict the Recurrence of Papillary Thyroid Carcinoma
    Han, Rui
    Sun, Wei
    Zhang, Hao
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
  • [50] Identification and Validation of an m6A-Related LncRNA Signature to Predict Progression-Free Survival in Colorectal Cancer
    Zhang, Yong
    Li, Lu
    Chu, Feifei
    Xiao, Xingguo
    Zhang, Li
    Li, Kunkun
    Wu, Huili
    PATHOLOGY & ONCOLOGY RESEARCH, 2022, 28